The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Managing side effects associated with lymphoma immunotherapies: beyond CRS & ICANS
Joshua Brody, MD, The Tisch Cancer Institute at Mount Sinai, New York City, NY, discusses side effects associated with administering immunotherapies for lymphoma. Dr Brody highlights that although severe CRS and ICANS can occur, they are rare, whereas more frequent toxicities, particularly infections, should be proactively managed with preventive measures such as vaccination and prophylactic antibiotics. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
